BAYN.DE Bayer Aktiengesellschaft
Company Analysis
Latest News
Bayer Gains FDA Review of Kerendia for Kidney Disease Without Diabetes
Bayer said the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) for Kerendia® (finerenone). The application seeks...
Bayer to Build $2.2 Billion Ohio Plant, Adding 600 Permanent Jobs
Bayer announced a $2.2 billion investment to build a pharmaceutical manufacturing facility in New Albany, Ohio. The project is part of the company’s long-term...
🔴 Bayer is trading 4.03% down today amid falling European shares
Bayer is trading at €46.02 (-4.03%) amid broader European market weakness. - European shares broadly fell on October 1 as investors turned risk-averse amid...
Bayer Secures FDA Priority Review for Lynkuet’s Hot Flashes in Breast Cancer
Bayer said the U.S. Food and Drug Administration (FDA) granted Priority Review to a supplemental New Drug Application for Lynkuet® (elinzanetant). The...
🔴 Bayer is trading 4.17% down
Bayer is trading 4.17% down at €48.68, with no clear company-specific catalyst identified for the September 29 decline. - A Reuters report published September...
Bayer Short Interest Jumps 183.4% in First Half of September
Bayer Aktiengesellschaft’s short interest rose 183.4% in the first half of September. At the end of August, 127,301 shares were sold short. By September 15,...
Bayer’s Kerendia Wins FDA Approval, First New T1D Kidney Drug in 30 Years
The U.S. Food and Drug Administration (FDA) approved Bayer’s Kerendia (finerenone) to treat chronic kidney disease (CKD) in adults with type 1 diabetes (T1D)....
Bayer closes €3B contraceptives deal, boosting capital for litigation costs
Bayer finalized a €3 billion capital agreement with investment firms Apollo and KKR. This transaction follows an initial announcement made on July 10. Apollo...
🟢 Bayer is trading 4% up today ahead of September 14, 2026 Roundup settlement hearing
Bayer is trading 4.01% up now at €50.10 as investors focus on the September 14, 2026 Missouri hearing for approval of Monsanto’s proposed $7.25 billion Roundup...
Bayer’s Hyrnuo Wins FDA Approval for First-Line Lung Cancer, 75% Response Rate
The U.S. Food and Drug Administration (FDA) granted accelerated approval for Bayer's cancer drug Hyrnuo (sevabertinib). This expanded indication allows Hyrnuo...
Bayer launches first of 10 blockbusters, targeting €500 million peak sales each
Bayer has launched the first products in a plan to release 10 blockbuster offerings. The company intends to launch these products over the next decade. Each...
Bayer's Lung Cancer Drug Hyrnuo Gains Approval in Japan
Bayer received approval for Hyrnuo (sevabertinib) from Japan's Ministry of Health, Labour and Welfare (MHLW). The approval date was August 24, 2026. Hyrnuo...
Bayer unveils Kerendia Phase III data, targeting kidney treatment growth
Bayer will present Phase III clinical trial data for cardiovascular, kidney, and stroke treatments at the ESC Congress 2026. The presentations highlight...
🟢 Bayer is trading 4.1% up today on upbeat quarterly results and improved margin outlook
Bayer is trading 4.1% up at €50.24 after investors reacted positively to latest quarterly results highlighting improving operating performance and a more...
🟢 Bayer is trading 4.6% up today after upbeat quarterly results and improved margin outlook
Bayer is trading 4.6% up at €49.31 after investors reacted positively to its latest quarterly results, which showed improving operating performance and a more...
Bayer fights to end Roundup litigation, aiming to clear financial overhang
Bayer will appear before a federal judge to dismantle ongoing litigation involving its Roundup weedkiller. The company inherited these extensive legal battles...
Bayer Upgraded to Buy by Goldman Sachs, Easing Glyphosate Legal Risks
Goldman Sachs analyst James Quigley upgraded Bayer Aktiengesellschaft to a Buy rating on July 6, 2026. Quigley increased the price target for the stock from...
🟢 BAYN.DE extends move to 5.3% up
BAYN.DE is trading at $51.58, up 5.3% versus the comparison close of $49.00 during regular trading. This is a price-movement alert; no separate...
🟢 BAYN.DE is trading 4.7% up today after Supreme Court ruling scales back Roundup litigation risk
BAYN.DE is trading at $51.30 (+4.69%) after the U.S. Supreme Court ruled 7-2 for Bayer in the Roundup warning-label dispute. • The decision significantly...
🟢 BAYN.DE is trading 5.2% up today after Supreme Court ruling scales back Roundup litigation risk
BAYN.DE is trading 5.2% up today at $48.41 after a U.S. Supreme Court decision scaled back Roundup cancer lawsuit risk. • The ruling triggered a sharp...